Does Rallies show Form 4 insider transactions for SUPN?

Yes. Rallies tracks SUPN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SUPN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SUPN. It does not provide personalized investment advice.

SUPN (Supernus Pharmaceuticals, Inc.) Stock Analysis - Insider Trades

Supernus Pharmaceuticals, Inc. (SUPN) is a publicly traded Healthcare sector company. As of May 21, 2026, SUPN trades at $48.40 with a market cap of $2.81B and a P/E ratio of -96.00. SUPN moved +2.27% today. Year to date, SUPN is -1.44%; over the trailing twelve months it is +46.66%. Its 52-week range spans $29.16 to $59.68. Analyst consensus is strong buy with an average price target of $63.17. Rallies surfaces SUPN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SUPN stock inside the company?

Recent SUPN insider activity includes Bhatt Padmanabh P. sold 6.84K, Bhatt Padmanabh P. sold 412, Bhatt Padmanabh P. sold 27.71K, Bhatt Padmanabh P. sold 22.29K, and Bhatt Padmanabh P. sold 34.11K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SUPN Key Metrics

Key financial metrics for SUPN
Metric	Value
Price	$48.40
Market Cap	$2.81B
P/E Ratio	-96.00
EPS	$-0.51
Dividend Yield	0.00%
52-Week High	$59.68
52-Week Low	$29.16
Volume	0
Avg Volume	0
Revenue (TTM)	$776.83M
Net Income	$-29.02M
Gross Margin	89.42%

Recent SUPN Insider Trades

Bhatt Padmanabh P. sold 6.84K (~$338.82K) on Mar 18, 2026.
Bhatt Padmanabh P. sold 412 (~$20.80K) on Mar 18, 2026.
Bhatt Padmanabh P. sold 27.71K (~$1.38M) on Mar 17, 2026.
Bhatt Padmanabh P. sold 22.29K (~$1.13M) on Mar 17, 2026.
Bhatt Padmanabh P. sold 34.11K (~$1.71M) on Mar 16, 2026.

Latest SUPN News

Supernus Pharmaceuticals Posts Record Q4 2025 Revenue Growth — Feb 25, 2026
Supernus Q4 Revenue Rises 21.5% to $211.6M; EPS of $0.92 Beats Estimates — Feb 25, 2026
Biogen Q4 Beat Sparks $66M Zurzuvae Sales, Boosting Supernus Partnership — Feb 6, 2026

SUPN Analyst Consensus

6 analysts cover SUPN: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.17.

Common questions about SUPN

Who is trading SUPN stock inside the company?: Recent SUPN insider activity includes Bhatt Padmanabh P. sold 6.84K, Bhatt Padmanabh P. sold 412, Bhatt Padmanabh P. sold 27.71K, Bhatt Padmanabh P. sold 22.29K, and Bhatt Padmanabh P. sold 34.11K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SUPN?: Yes. Rallies tracks SUPN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SUPN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SUPN. It does not provide personalized investment advice.